Loading...
•
Mar 31, 2022
Protalix Q1 2022 Earnings Report
Protalix reported an increase in revenue and a reduced net loss compared to the same period last year.
Key Takeaways
Protalix BioTherapeutics reported a strong first quarter with a 100% increase in revenue from selling goods and a significant reduction in net loss. Positive clinical trial results for PRX-102 and regulatory advancements in Europe highlight the company's progress in treating Fabry disease.
Revenues from selling goods increased by 100% to $9.0 million compared to Q1 2021.
Revenue from licenses and R&D services increased slightly to $7.1 million.
Net loss decreased to $2.3 million, or $0.05 per share, compared to a net loss of $5.5 million, or $0.14 per share, in Q1 2021.
Positive results from Phase III clinical trials for PRX-102 were announced, supporting BLA resubmission to the FDA.
Forward Guidance
The company did not provide forward guidance in this report.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...